Navigation Links
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Date:8/31/2007

eing investigated to address LDL-C, HDL-C and triglycerides simultaneously in a single pill, which could improve convenience and lipid outcomes.

Abbott will continue executing the clinical trial program and be responsible for regulatory registration of the new combination therapy. AstraZeneca will hold the New Drug Application. Following successful completion of the clinical program, a regulatory application for the new combination therapy is targeted for submission in 2009. This collaboration relates to the US market.

About ABT-335

ABT-335 is a next-generation fenofibrate in clinical development for abnormal lipids in the bloodstream, including cholesterol and triglycerides. In addition, based on the positive results from ABT-335's clinical trial program, Abbott plans to file ABT-335 as a monotherapy (as an adjunct to diet) by the end of 2007. Abbott is currently evaluating ABT-335 as a

co-administered therapy with other on-market statins, including CRESTOR, and expects to present data from the clinical trials in the first half of 2008.

About CRESTOR(R)

CRESTOR (rosuvastatin calcium) is a once-daily, lipid-lowering agent prescription medication for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. It is a member of the statin (HMG-CoA reductase inhibitors) class of drug therapy. CRESTOR has not been determined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. However, initiation of therapy with 5 mg once daily should be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy, and for special populations such as patients taking cyclosporine, Asian patients, and patients with severe renal insufficiency. For patients with marked hypercholestero
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) ... to consider: , 1. The appropriate ... 2. The potential for adverse cardiovascular outcomes ... litigation ongoing, an informally-organized litigation group subcommittee prepared a ... replacement therapy. Among others, ZKB attorney Michelle L. Kranz ...
(Date:9/17/2014)... BOSTON September 17, 2014 Why are Asian ... than Caucasian Americans, and prone to develop the disease ... may lie in the transition from traditional high-fiber, low-fat ... extra risks for those of Asian heritage, says George ... at Joslin Diabetes Center and the senior author of ...
(Date:9/17/2014)... New York, NY (PRWEB) September 17, 2014 ... morcellators ( http://www.drugbot.com/morcellator/ ) in laparoscopic hysterectomies and other ... LLP reports. According to figures posted on Change.org, at ... September 17th. * , According to a recent report ... one year ago by Dr. Hooman Noorchashm, after his ...
(Date:9/17/2014)... 17, 2014 Cadiz Laser Spa ... cosmetic procedures to clients throughout Central Texas. The ... is Collagen Induction Therapy. Using the revolutionary Rejuvapen ... to help clients correct a wide variety of ... month, and Cadiz Laser Spa is currently offering ...
Breaking Medicine News(10 mins):Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2
... Extended One Year -LEXINGTON, Mass., Jan. 26 ... Chain Systems has extended its contract to offer ... This continues a successful history between the two ... contract covers IL,s portfolio of critical care analyzers, ...
... Medimetriks Pharmaceuticals announced today that the ... Company (Nasdaq: PRGO ), a leading manufacturer ... Exclusive Authorized Distributor of generic versions of Medimetriks, branded ... Medimetriks to receive a percentage of Perrigo,s Net Sales ...
... Authentidate Holding Corp. (Nasdaq: ADAT ... Exchange and workflow management services, announced today that ... LLC and Parascript Management, Inc. (collectively "Parascript") that ... Merger it entered into with Authentidate. The merger ...
... company awardIRVINE, Calif., Jan. 26 ChromaDex Corporation, ... reference standards and contract research, announced today that ... and alternative health care magazine, selected the Company ... Award recipients for its achievement in setting stevia ...
... Jan. 26 Trintech Group Plc (Nasdaq: ... governance, transaction risk management, and compliance solutions, today announced ... will meet on January 27 in Mountain View, California ... to share common experiences, discuss the latest market trends ...
... Health System announced,that it has launched the International ... for robotic surgical teams from around the world.,The launch ... annual,meeting in San Francisco. , ... robotic-assisted,surgery since we began our program in 2002," says ...
Cached Medicine News:Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 2Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 3Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 2Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 3Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 2Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 3Health News:Saint Joseph's Launches International College of Robotic Surgery 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: